Register Login
Register to leave comments
  • News bot March 26, 2026, 8:25 p.m.

    📋 ZENTALIS PHARMACEUTICALS, INC. (ZNTL) - Financial Results

    Filing Date: 2026-03-26

    Accepted: 2026-03-26 16:24:44

    Event Type: Financial Results

    Event Details:

    ZENTALIS PHARMACEUTICALS, INC. (ZNTL) Reports the reporting period Financial Results ZENTALIS PHARMACEUTICALS, INC. (ZNTL) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 67425
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 245893
      • anticipated by year-end. Results from the DENALI Part 2 trial could potentially support accelerated approval, pending study outcome,” said Julie Eastland, Chief Executive Officer. “In parallel, we expect to initiate the randomized Phase 3 confirmatory trial to support potential full approval, known as ASPENOVA, in the first half of 2026
      • expected by year end 2026
      • expected in the 1H 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2024 2023 Change ($) Change (%)
    Operating Expenses Loss From Operations -191.19K -191.19K $0.00 +0.00%
    Other Income Expense Net Loss -165.87K -165.87K $0.00 +0.00%
    Other Income Expense Weighted Average Shares 71.08K 71.08K $0.00 +0.00%
    Cash Equivalents Marketable Securities 245.89K 245.89K $0.00 +0.00%
    Loss from Operations -152.81K -191.19K $38.39K +20.08%
    Other Income, Net 16.19K 25.50K $-9.31K -36.52%
    Net Loss -136.62K -165.69K $29.07K +17.55%
    Cash and Marketable Securities 245.89K 245.89K $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ZENTALIS PHARMACEUTICALS, INC.
    • Ticker Symbol: ZNTL

Search

News categories